Views & Analysis | Perspectives on pharma industry issues

R&D

Alzheimer's research is moving toward more selective targets

As we mark World Alzheimer’s Day, it is worth reflecting on the progress made in recent years.

Market Access

$100 notes in pill bottle on aquamarine background with spilled pills

How new PBM transparency rules will alter drug pricing

The complex drug pricing ecosystem means all stakeholders are scrambling to understand how the new regulations and PBMs’ adjustments will impact them.

Market Access

From first approval to lasting value: What sets successful e...

Approval may validate the science, but it does not secure commercial success. That outcome is determined by the decisions made before launch.

Market Access

drug pricing in the UK, pills overlain on map

Request to look further into NICE non-submissions in the fut...

Leela Barham looks at the discussion on non-submissions to the HTA body NICE, informed by the latest metrics for VPAG.

R&D

Changing Faces: Board of Director and Advisory Board hires, ...

Boardrooms, Advisory Boards, and governance teams saw plenty of activity in August.

Articles

Tunnah’s musings: Skydiving pharma and the art of fall bette...

In the latest musings from our own Paul Tunnah, he wonders whether the patent cliff for pharma looks a little shallow compared to a 39km jump from space. Did you watch Felix Baumgartner jump out of that tiny capsule in the stratosphere at 128,000 feet as the first step on his way to breaking the sound barrier…

Articles

Global content management part 1: Collaboration without boun...

Jen Goldsmith outlines the collaborative new business model that the life sciences industry is embracing in the first of this two-part article. Over the last 10 years or more, the global population of African wild dogs has been shrinking rapidly, to the point of being listed as an...

Articles

Revolutionising healthcare - making the impossible possible

We interview Eileen Bartholomew of the X PRIZE Foundation on its goals and how it intends to change people’s mindsets of what is possible. The X PRIZE foundation was founded in 1996 with the intention of launching large scale incentive prizes to not only achieve...

Sales & Marketing

The patient communication crisis pharma can no longer ignore

Industry's significant investments in patient engagement are only effective if patients trust the communication enough to answer in the first place.

Sales & Marketing

Wooden pawns representing number of employees

Headcount is not a growth strategy

Deciding when, where, and how quickly to add headcount is rarely straightforward.

Digital

Pharma brands face golden opportunity to extend supply chain...

People are ready for technology that verifies authenticity and provides helpful information directly from the medicinal product itself.

Digital

Changing Faces: Digital and supplier hires, August 2026

Digital health, clinical technology, contract services, and life sciences suppliers all saw notable leadership changes last month.

Market Access

How new PBM transparency rules will alter drug pricing

The complex drug pricing ecosystem means all stakeholders are scrambling to understand how the new regulations and PBMs’ adjustments will impact them.

Market Access